SCHEMBL24449136

SCHEMBL24449136

CN1CCN(Cc2ccc(NC(=O)Cc3ccc(-c4cnn(-c5cccnc5N)c4)cc3)cc2C(F)(F)F)CC1

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ ABL1 P00519 10/20 0.51
▸ MKNK2 Q9HBH9 6/20 0.51
▸ MKNK1 Q9BUB5 5/20 0.51
▸ BCR P11274 4/20 0.51
▸ SRC P12931 3/20 0.49
▸ CDK8 P49336 2/20 0.48
▸ CDK1 P06493 1/20 0.48
▸ CDK2 P24941 1/20 0.48
▸ FGFR4 P22455 1/20 0.48
▸ RET P07949 1/20 0.48
▸ KIF5B P33176 1/20 0.48
▸ CCDC6 Q16204 1/20 0.48
▸ ABL2 P42684 1/20 0.47
▸ MAPK14 Q16539 1/20 0.47
▸ CSF1R P07333 1/20 0.47
▸ KIT P10721 1/20 0.47
▸ EGFR P00533 1/20 0.47
▸ BRAF P15056 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24449287 0.91 ABL1 (0.59) ABL1BCRSRCCDK8CDK1
SCHEMBL24449285 0.90 ABL1 (0.57) ABL1BCRRETKIF5BCCDC6
SCHEMBL24449140 0.88 ABL1 (0.50) ABL1MKNK2MKNK1BCRSRC
SCHEMBL24449261 0.87 KIT (0.58) ABL1BCRRETKIF5BCCDC6
SCHEMBL24449097 0.86 AXL (0.43) ABL1MKNK2MKNK1BCRSRC
SCHEMBL24449099 0.84 ABL1 (0.55) ABL1BCRSRCCDK8CDK1
SCHEMBL29350267 0.79 ABL1 (0.62) ABL1MKNK2MKNK1BCRSRC
SCHEMBL21176137 0.79 ABL1 (0.62) ABL1MKNK2MKNK1BCRSRC
SCHEMBL24449233 0.79 FGFR4 (0.60) ABL1SRCCDK8CDK1CDK2
SCHEMBL24449137 0.79 ABL1 (0.58) ABL1BCRSRCCDK8CDK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220160705-A1 METHODS FOR CONTROLLING PROSTAGLANDIN-MEDIATED BIOLOGICAL PROCESSES CORNELL UNIVERSITY 2022-05-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220160705-A1 METHODS FOR CONTROLLING PROSTAGLANDIN-MEDIATED BIOLOGICAL PROCESSES PTGES, PTGS1, PTGES2 ABL1 4516/4885MKNK2 3436/4885MKNK1 3866/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback